Evotec SE and Bristol-Myers Squibb (BMS) are expanding an existing iPSC (induced pluripotent stem cells) collaboration. Evotec has received a $6 million payment from BMS following the decision to expand the collaboration to include additional cell lines.   Evotec and Celgene, which is now a BMS company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of...